Format

Send to

Choose Destination
See comment in PubMed Commons below
Endocrinol Nutr. 2011 Feb;58(2):75-83. doi: 10.1016/j.endonu.2010.09.007. Epub 2011 Jan 17.

[Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].

[Article in Spanish]

Author information

1
Departament de Medicina, Universitat Autònoma de Barcelona, Badalona, Barcelona, España. reverter.germanstrias@gencat.cat

Erratum in

  • Endocrinol Nutr. 2011 Jun-Jul;58(6):321.

Abstract

In patients with differentiated thyroid carcinoma, long-term inhibition of thyrotropin (TSH) secretion through levothyroxine administration is required when there is evidence of persistent or recurrent disease. In these cases, levothyroxine doses should be monitored to achieve the objectives of inhibiting TSH and avoiding clinical hyperthyroidism. The possibility that suppressive therapy may produce deleterious effects is still controversial, mainly in elderly patients. There are many studies on the potential harmful effects of suppressive therapy on various organs and systems with discrepant results. However, there is no scientific evidence that the clinical impact of these effects is significant.

PMID:
21247815
DOI:
10.1016/j.endonu.2010.09.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Support Center